Investigational Weight Management Drug Retatrutide Only Available Via Clinical Trials

Retatrutide, a promising GLP-1 receptor agonist for weight management and type 2 diabetes, is currently an investigational drug without FDA approval. Access is limited to participation in registered clinical trials. Patients are urged to consult healthcare providers for approved alternatives and to avoid potentially hazardous, unregulated online sources. This guidance aims to ensure patient safety and proper access to medication.